Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 plus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
CTR20220174Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nisevokitug in pancreatic adenocarcinoma (PDAC), sponsored by Novartis. Started Jan 2022; status: completed.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20220174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220174.